Spots Global Cancer Trial Database for metastatic breast cancer (mbc)
Every month we try and update this database with for metastatic breast cancer (mbc) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea | NCT05132101 | Metastatic Brea... | Patients who re... | 18 Years - | Pfizer | |
| Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer | NCT01495247 | Inoperable Loca... Metastatic Brea... | BEZ235 Paclitaxel | 18 Years - | Novartis | |
| Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer | NCT02312622 | Stage IV Non-sm... Recurrent Non-s... Extensive-stage... Recurrent Small... Tumors Metastat... Metastatic Brea... | Pegylated Irino... | 18 Years - | Stanford University | |
| Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer | NCT02312622 | Stage IV Non-sm... Recurrent Non-s... Extensive-stage... Recurrent Small... Tumors Metastat... Metastatic Brea... | Pegylated Irino... | 18 Years - | Stanford University | |
| Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings. | NCT05155566 | Breast Cancer M... | 18 Years - | Pfizer | ||
| Paclitaxel Polymeric Micelles for Injection Versus TPC on the Treatment of HER2-negative Metastatic Breast Cancer (MBC). | NCT06143553 | Metastatic Brea... | Paclitaxel Poly... Eribulin Mesila... Capecitabine Ta... Gemcitabine Hyd... Vinorelbine Tar... Paclitaxel (alb... | 18 Years - | Shanghai Yizhong Pharmaceutical Co., Ltd. | |
| Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer | NCT02312622 | Stage IV Non-sm... Recurrent Non-s... Extensive-stage... Recurrent Small... Tumors Metastat... Metastatic Brea... | Pegylated Irino... | 18 Years - | Stanford University | |
| Swedish Ibrance Registries Insights (SIRI) | NCT04654208 | Malignant Neopl... | palbociclib | 18 Years - 99 Years | Pfizer | |
| Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea | NCT05132101 | Metastatic Brea... | Patients who re... | 18 Years - | Pfizer | |
| Phase III Study of Two Different Schedules (Weekly and Tri-weekly) of Combination of Gemcitabine and Two Taxanes in MBC | NCT00236899 | Metastatic Brea... | Gemcitabine Docetaxel Paclitaxel | 18 Years - | Eli Lilly and Company | |
| Study of Cabozantinib (XL184) in Adults With Advanced Malignancies | NCT00940225 | Solid Tumors Cancer | Cabozantinib Placebo | 18 Years - | Exelixis | |
| Study of Cabozantinib (XL184) in Adults With Advanced Malignancies | NCT00940225 | Solid Tumors Cancer | Cabozantinib Placebo | 18 Years - | Exelixis | |
| Study of Cabozantinib (XL184) in Adults With Advanced Malignancies | NCT00940225 | Solid Tumors Cancer | Cabozantinib Placebo | 18 Years - | Exelixis | |
| Phase III Study of Two Different Schedules (Weekly and Tri-weekly) of Combination of Gemcitabine and Two Taxanes in MBC | NCT00236899 | Metastatic Brea... | Gemcitabine Docetaxel Paclitaxel | 18 Years - | Eli Lilly and Company | |
| Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea | NCT05132101 | Metastatic Brea... | Patients who re... | 18 Years - | Pfizer |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
